Analysts Anticipate AVEO Pharmaceuticals, Inc. (AVEO) Will Announce Quarterly Sales of $2.48 Million

Wall Street brokerages predict that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will post $2.48 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for AVEO Pharmaceuticals’ earnings. The highest sales estimate is $2.80 million and the lowest is $2.15 million. AVEO Pharmaceuticals reported sales of $80,000.00 in the same quarter last year, which indicates a positive year-over-year growth rate of 3,000%. The firm is expected to issue its next earnings results on Tuesday, March 12th.

On average, analysts expect that AVEO Pharmaceuticals will report full year sales of $5.77 million for the current financial year, with estimates ranging from $4.00 million to $6.70 million. For the next financial year, analysts expect that the company will post sales of $11.88 million, with estimates ranging from $5.00 million to $24.30 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover AVEO Pharmaceuticals.

AVEO Pharmaceuticals (NASDAQ:AVEO) last announced its quarterly earnings results on Friday, November 9th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. The firm had revenue of $2.47 million for the quarter, compared to analyst estimates of $0.68 million.

Several equities research analysts have recently issued reports on the company. National Securities lowered AVEO Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Tuesday, November 6th. Zacks Investment Research lowered AVEO Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 23rd. HC Wainwright set a $7.00 price target on AVEO Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, October 23rd. B. Riley reiterated a “neutral” rating and set a $1.00 price target (down from $5.00) on shares of AVEO Pharmaceuticals in a report on Monday, February 4th. Finally, BidaskClub lowered AVEO Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 19th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $2.21.

Shares of AVEO Pharmaceuticals stock remained flat at $$0.59 during trading on Monday. The stock had a trading volume of 2,706,318 shares, compared to its average volume of 3,321,314. The firm has a market cap of $73.96 million, a price-to-earnings ratio of -3.66 and a beta of 1.26. AVEO Pharmaceuticals has a fifty-two week low of $0.56 and a fifty-two week high of $3.59.

In related news, Director Anthony B. Evnin sold 325,139 shares of the firm’s stock in a transaction that occurred on Wednesday, November 14th. The stock was sold at an average price of $1.90, for a total value of $617,764.10. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Equity Opportunities Iv Growth acquired 1,200,000 shares of the business’s stock in a transaction that occurred on Monday, November 19th. The stock was bought at an average cost of $1.86 per share, for a total transaction of $2,232,000.00. The disclosure for this purchase can be found here. Insiders purchased a total of 2,358,709 shares of company stock worth $4,272,673 over the last three months. 4.40% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. raised its stake in shares of AVEO Pharmaceuticals by 2.1% in the 3rd quarter. BlackRock Inc. now owns 7,120,894 shares of the biopharmaceutical company’s stock valued at $23,570,000 after acquiring an additional 143,148 shares in the last quarter. NEA Management Company LLC increased its position in AVEO Pharmaceuticals by 5.1% in the 3rd quarter. NEA Management Company LLC now owns 18,698,038 shares of the biopharmaceutical company’s stock worth $61,891,000 after buying an additional 914,316 shares during the period. Hikari Power Ltd bought a new position in AVEO Pharmaceuticals in the 4th quarter worth approximately $128,000. Schwab Charles Investment Management Inc. increased its position in AVEO Pharmaceuticals by 661.9% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 218,129 shares of the biopharmaceutical company’s stock worth $493,000 after buying an additional 189,500 shares during the period. Finally, MetLife Investment Advisors LLC bought a new position in AVEO Pharmaceuticals in the 3rd quarter worth approximately $275,000. 42.03% of the stock is currently owned by institutional investors and hedge funds.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

See Also: Current Ratio

Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply